Keros rebuilt around a muscle-wasting ActA/ActB trap after a PAH safety halt; the case turns on whether Phase 1 PD signals in healthy volunteers translate to functional benefit in DMD

Keros is a clinical-stage company developing a targeted protein-replacement therapy for Duchenne muscular dystrophy, a fatal muscle-wasting disease; the therapy is not yet approved.

After halting cibotercept in PAH due to pericardial effusions, Keros redeployed its ActA/ActB ligand-trap platform into DMD, a fatal muscle-wasting disease where rinvatercept showed increased lean mass and bone density in Phase 1 healthy volunteers. The thesis turns on whether those pharmacodynamic signals translate to meaningful functional benefit in DMD patients when Phase 2 efficacy data arrive. The central risk is that Phase 1 data in healthy subjects are purely mechanistic, with no prior human efficacy in diseased muscle and a competitive DMD field already featuring approved exon-skipping and gene-replacement approaches.